Cite
HARVARD Citation
Cramer, P. et al. (n.d.). Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leukemia & lymphoma. 54 (8), pp. 1821-1822. [Online].